Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
123764183 | 12376418 | 3 | F | 20160209 | 20160705 | 20160517 | 20160712 | EXP | JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-020554 | BRISTOL MYERS SQUIBB | 74.00 | YR | M | Y | 0.00000 | 20160712 | CN | JP | JP |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
123764183 | 12376418 | 1 | PS | NIVOLUMAB | NIVOLUMAB | 1 | Intravenous drip | 3 MG/KG, QD | 3 | MG/KG | 125554 | 3 | MG/KG | SOLUTION FOR INJECTION | QD | ||||
123764183 | 12376418 | 2 | SS | IRESSA | GEFITINIB | 1 | Oral | UNK | U | 0 | TABLET |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
123764183 | 12376418 | 1 | Non-small cell lung cancer recurrent |
123764183 | 12376418 | 2 | Non-small cell lung cancer recurrent |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
123764183 | 12376418 | DE |
123764183 | 12376418 | HO |
123764183 | 12376418 | OT |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
123764183 | 12376418 | Interstitial lung disease |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
123764183 | 12376418 | 1 | 20160114 | 20160114 | 0 | |
123764183 | 12376418 | 2 | 20160203 | 0 |